Orchid Pharma

Who are the top shareholders of the Orchid Pharma?

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited with a 69.84% stake, mutual funds at 18.79% (led by Quant Small Cap Fund at 6.83%), Foreign Institutional Investors at 2.69%, and individual investors holding 5.11%. There are no pledged promoter holdings reported.

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited, which holds the highest promoter stake at 69.84%. Additionally, mutual funds collectively hold 18.79% of the shares, with the Quant Mutual Fund - Quant Small Cap Fund being the largest public shareholder at 6.83%. Foreign Institutional Investors (FIIs) have a stake of 2.69%, and individual investors hold 5.11% of the shares. There are no pledged promoter holdings reported.

how big is Orchid Pharma?

As of Jun 06, Orchid Pharma Ltd has a market capitalization of 3,636.56 Cr, with recent net sales of 921.93 Cr and a net profit of 99.66 Cr. Shareholder's funds are 1,169.47 Cr, and total assets amount to 1,553.87 Cr.

Market Cap: As of Jun 06, Orchid Pharma Ltd has a market capitalization of 3,636.56 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 921.93 Cr and a net profit of 99.66 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in Mar 24. Shareholder's funds are reported at 1,169.47 Cr, while total assets amount to 1,553.87 Cr.

Has Orchid Pharma declared dividend?

Orchid Pharma has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 13, 2012. However, the dividend yield is 0%, and total returns have shown significant volatility, with notable gains over the 5-year period despite recent declines.

Orchid Pharma Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3<BR>- Ex-date: 13 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -59.45%, the dividend return was 0%, resulting in a total return of -59.45%.<BR><BR>For the 1-year period, the price return was -32.95%, the dividend return was 0%, leading to a total return of -32.95%.<BR><BR>Over the 2-year period, the price return was 72.37%, with a dividend return of 0%, resulting in a total return of 72.37%.<BR><BR>In the 3-year period, the price return was 137.39%, the dividend return was 0%, culminating in a total return of 137.39%.<BR><BR>For the 4-year period, the price return was -49.4%, with a dividend return of 0%, leading to a total return of -49.4%.<BR><BR>In the 5-year period, the price return was 13462.86%, with a dividend return of 0%, resulting in a total return of 13462.86%.<BR><BR>Overall, while Orchid Pharma has declared a dividend, the dividend yield remains at 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant volatility, with substantial gains over longer periods, particularly in the 5-year timeframe.

Who are the peers of the Orchid Pharma?

Orchid Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, IOL Chemicals, Novartis India, Senores Pharma, SMS Pharma, and Zota Health Care. Orchid Pharma has below-average management risk, growth, and capital structure, with a 1-year return of -31.39%, the lowest among its peers.

Peers: The peers of Orchid Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, IOL Chemicals, Novartis India, Senores Pharma., SMS Pharma, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is present at IOL Chemicals and Novartis India, while Below Average management risk is noted for Orchid Pharma and Senores Pharma. Excellent growth is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Senores Pharma, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Orchid Pharma, IOL Chemicals, SMS Pharma, and Zota Health Care. Excellent capital structure is found at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Divi's Lab., IOL Chemicals, and Novartis India, while Good capital structure is seen at Torrent Pharma and Senores Pharma, and Below Average capital structure is noted for Orchid Pharma and SMS Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Orchid Pharma has the lowest at -31.39%. Orchid Pharma's return is significantly lower than all peers. Additionally, the six-month return is negative for Orchid Pharma, Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, and Zota Health Care.

Who are in the management team of Orchid Pharma?

As of March 2023, the management team of Orchid Pharma includes Tanu Singla, Dharam Vir, Mudit Tandon, Manoj Goyal (all Independent Directors), Manish Dhanuka (Managing Director), Mridul Dhanuka (Whole-time Director), Ram Gopal Agarwal (Chairman), and Marina Peter (Company Secretary & Compliance Officer).

As of March 2023, the management team of Orchid Pharma includes the following individuals:<BR><BR>1. Tanu Singla - Independent Director<BR>2. Dharam Vir - Independent Director<BR>3. Mudit Tandon - Independent Director<BR>4. Manoj Goyal - Independent Director<BR>5. Manish Dhanuka - Managing Director<BR>6. Mridul Dhanuka - Whole-time Director<BR>7. Ram Gopal Agarwal - Chairman (Non-Executive)<BR>8. Marina Peter - Company Secretary & Compliance Officer<BR><BR>These individuals play key roles in the governance and management of the company.

What does Orchid Pharma do?

Orchid Pharma Ltd is a leading Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 3,789 Cr and reported net sales of 2,375 Cr and net profit of 223 Cr for March 2025. The company has a P/E ratio of 38.00 and a return on equity of 7.86%.

Overview:<BR>Orchid Pharma Ltd is a leading pharmaceutical company in India, operating in the Pharmaceuticals & Biotechnology industry and classified as a Small Cap.<BR><BR>History:<BR>Orchid Pharma was incorporated in an unspecified year and has undergone various status changes. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,375 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 223 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: INR 3,789 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 38.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.00<BR>- Return on Equity: 7.86%<BR>- Price to Book: 2.96<BR><BR>Contact Details:<BR>- Address: Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road Chennai Tamil Nadu : 600034<BR>- Tel: 91-44-28211000/28230000<BR>- Email: corporate@orchidpharma.com<BR>- Website: http://www.orchidpharma.com

Is Orchid Pharma overvalued or undervalued?

As of July 21, 2025, Orchid Pharma is considered overvalued with a PE ratio of 36.74 and an EV to EBITDA of 31.21, significantly higher than its peers, and has underperformed with a year-to-date return of -60.27% compared to the Sensex's gain of 5.20%.

As of 21 July 2025, Orchid Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its relative valuation. Despite this change, the company appears to be overvalued based on its current financial metrics. The PE ratio stands at 36.74, while the EV to EBITDA ratio is 31.21, both of which are significantly higher than many of its peers. Additionally, the PEG ratio of 4.17 suggests that the stock may be priced too high relative to its growth prospects.<BR><BR>In comparison to its peers, Sun Pharma has a PE of 35.52 and an EV to EBITDA of 25.11, while Cipla shows a more attractive valuation with a PE of 22.6 and an EV to EBITDA of 15.65. These comparisons highlight that Orchid Pharma's valuation is not justified when considering its earnings and growth potential. Furthermore, the company's year-to-date return of -60.27% starkly contrasts with the Sensex's gain of 5.20%, reinforcing the notion that Orchid Pharma is currently overvalued.

When is the next results date for Orchid Pharma?

The next results date for Orchid Pharma is 12 August 2025.

The next results date for Orchid Pharma is scheduled for 12 August 2025.

How has been the historical performance of Orchid Pharma?

Orchid Pharma has shown significant financial improvement from March 2023 to March 2025, with net sales increasing from 665.90 Cr to 921.93 Cr, and consolidated net profit rising from 46.32 Cr to 99.66 Cr, indicating strong recovery and growth. Total assets and liabilities grew in tandem, while cash flow from operations improved markedly.

Answer:<BR>The historical performance of Orchid Pharma shows a significant improvement in financial metrics over the years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Orchid Pharma's net sales have steadily increased from 665.90 Cr in March 2023 to 921.93 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 665.90 Cr to 921.93 Cr during the same period. The company's operating profit (PBDIT) also improved significantly, increasing from 103.05 Cr in March 2023 to 144.65 Cr in March 2025, although the operating profit margin slightly decreased from 12.56% to 12.71%. Profit before tax rose from 55.25 Cr to 95.56 Cr, and profit after tax increased from 55.25 Cr to 95.76 Cr, indicating a strong recovery from previous losses. The consolidated net profit showed a remarkable increase from 46.32 Cr in March 2023 to 99.66 Cr in March 2025. On the balance sheet, total assets grew from 1,225.21 Cr to 1,687.91 Cr, while total liabilities increased from 1,225.21 Cr to 1,687.91 Cr, reflecting a balanced growth in both assets and liabilities. Cash flow from operating activities improved, with a net cash inflow of 17.00 Cr in March 2025 compared to a net outflow of 19.00 Cr in March 2024. Overall, Orchid Pharma's financial performance demonstrates a strong recovery and growth in key areas over the past few years.

Is Orchid Pharma technically bullish or bearish?

As of December 4, 2025, the trend has shifted to mildly bullish, supported by daily moving averages and a bullish RSI on the monthly chart, though mixed signals from the MACD and Bollinger Bands indicate divergence between short-term and long-term trends.

As of 4 December 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating bullish momentum. The weekly MACD is also mildly bullish, while the monthly MACD remains bearish, suggesting mixed signals across time frames. The RSI shows a bullish signal on the monthly chart, but no signal on the weekly, indicating potential strength in the longer term. Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, adding to the mixed outlook. Overall, the strength of the bullish stance is moderate, with key indicators showing divergence between short-term and long-term trends.

Are Orchid Pharma Ltd latest results good or bad?

Orchid Pharma Ltd's latest results are concerning, showing a consolidated net loss of ₹12.61 crore for Q3 FY26, a 160.68% decline year-on-year, and a significant drop in profitability with operating margins at just 0.76%. Overall, the financial performance indicates ongoing structural challenges, marking the results as bad.

Orchid Pharma Ltd's latest results indicate a troubling financial situation. For Q3 FY26, the company reported a consolidated net loss of ₹12.61 crore, which is a significant decline of 160.68% year-on-year. This marks the second consecutive quarter of losses, following a loss of ₹5.72 crore in the previous quarter.<BR><BR>Net sales for the quarter were ₹207.27 crore, reflecting a 4.63% decrease compared to the same period last year, although there was a slight sequential recovery of 7.11% from the previous quarter. However, this modest revenue growth is overshadowed by the severe drop in profitability, with operating margins collapsing to just 0.76%, down from 12.13% a year ago.<BR><BR>The company has faced a dramatic erosion in profitability over the nine-month period ending December 2025, with consolidated profit plummeting 95.23% to ₹3.69 crore compared to ₹77.37 crore in the same period of FY25. This suggests deep operational challenges that have significantly impacted Orchid Pharma's ability to generate profitable sales.<BR><BR>Overall, the financial performance points to a company in distress, with critical red flags such as negative operating margins, weak return metrics, and a substantial decline in profitability. The market has reacted negatively, with the stock underperforming the broader market significantly. Given these factors, the latest results can be characterized as bad, reflecting ongoing structural issues rather than temporary setbacks.

Should I buy, sell or hold Orchid Pharma Ltd?

Which are the latest news on Orchid Pharma?

Why is Orchid Pharma Ltd falling/rising?

As of 10-May, Orchid Pharma Ltd's stock price is rising to 704.10, up 3.33%. This increase is driven by strong short-term performance and high institutional holdings, despite ongoing long-term fundamental challenges.

As of 10-May, Orchid Pharma Ltd's stock price is rising, currently at 704.10, reflecting a change of 22.7 (3.33%) upward. This increase can be attributed to several factors. The stock has outperformed its sector by 3.2% today and has experienced consecutive gains over the last three days, accumulating a total return of 12.35% during this period. Additionally, the stock opened with a gain of 2% today and reached an intraday high of Rs 705.75, indicating strong buying interest.<BR><BR>Moreover, the stock has shown significant short-term performance, with a 1-week return of +12.03% compared to the Sensex's +0.54%, and a remarkable 1-month return of +31.01% while the benchmark has slightly declined by 0.30%. This positive momentum is further supported by high institutional holdings at 21.12%, which have increased by 0.56% over the previous quarter, suggesting confidence from more knowledgeable investors.<BR><BR>However, it is important to note that despite the recent rise, the company has faced challenges in its long-term fundamentals, including negative results for the last five consecutive quarters and a weak return on equity (ROE) of 4.62%. While these factors may raise concerns about the sustainability of the stock's upward movement, the current price increase appears to be driven by short-term trading dynamics and investor sentiment rather than long-term financial health.